Literature DB >> 11859947

Gemcitabine-induced acute lipodermatosclerosis-like reaction.

C Y Chu1, C H Yang, H C Chiu.   

Abstract

Gemcitabine is considered to be a well-tolerated and safe cytostatic drug because of the relative lack of side effects. Cutaneous reactions due to gemcitabine treatment, including alopecia and maculopapular eruption, are well known. We report one patient with squamous cell carcinoma of the lung who developed a gemcitabine-induced cutaneous reaction mimicking acute lipodermatosclerosis. This case has never been reported in the literature before.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11859947     DOI: 10.1080/000155501317208381

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  5 in total

1.  Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma.

Authors:  Jillian W Millsop; Victoria R Sharon; Tatyana Petukhova; Maxwell A Fung; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2016-10-24       Impact factor: 1.587

2.  Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenon.

Authors:  Amit Mittal; Jonathan S Leventhal
Journal:  JAAD Case Rep       Date:  2017-04-14

3.  Skin Necrosis Due to the Extravasation of Irritant Anticancer Agents.

Authors:  Hiroto Okuda; Asako Masatsugu; Takako Sijimaya; Rie Arai
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

4.  Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?

Authors:  Amy X Du; Robert Gniadecki; Jan Storek; Mohamed Osman
Journal:  Front Med (Lausanne)       Date:  2022-02-24

5.  Gemcitabine-induced extensive skin necrosis.

Authors:  Sara D'epiro; Monica Salvi; Carlo Mattozzi; Simona Giancristoforo; Marco Campoli; Ramona Zanniello; Cecilia Luci; Laura Macaluso; Sara Giovannoni; Roberto Iacovelli; Stefano Calvieri; Antonio Giovanni Richetta
Journal:  Case Rep Med       Date:  2012-11-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.